Audit: QRS - Aviptadil for Health & Longevity
Audit conducted on 12/09/2026 15:44 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: at-a-glance vs ER Conclusion (l.488-492), protocol cells vs ER Therapeutic Protocol (l.351-355), time cells vs Practical Considerations (l.412), benefit/risk tiers vs ER headings (l.140-194, l.218-274), gates vs l.296-325, monitoring vs l.442-455, qualitative vs l.459-464. No unsupported claim found. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | marker_6_target keeps the ER’s “No established treatment target” hedge (QRS l.721-724 vs ER l.449); speculative tiers carry no strengthened wording. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication strength preserved (e.g. ER “Pregnant or breastfeeding women outside a supervised protocol” -> QRS l.577 “Pregnancy or breastfeeding outside a supervised protocol”); at-a-glance keeps “but not survival”. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | stop_items map 1:1 to the ER’s “Populations who should avoid Aviptadil” list; caution_items map to the ER interaction bullets. No Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT ids, author names or brand names in the QRS. All named drugs and botanicals (sildenafil, tadalafil, alprostadil, papaverine, doxazosin, amlodipine, sacubitril/valsartan, Ginkgo biloba, Curcuma longa, etc.) appear in ER l.296-314. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, evidence-weighted register throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and objective; protocol and monitoring panels are data-driven without hype. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as evidence and labelled regimen, not as instruction to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advisory constructions; regimens and cadence are described, not prescribed. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise”, “consider” or “should” in any rendered text (the only “Must” match is in a template CSS comment at l.130). |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are the ER’s own biomarker and indication names, which are load-bearing; hs-CRP is expanded at l.705-707. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | All entries are single-clause; benefit and risk tiers are reduced to semicolon-joined ER headings. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framed for a proactive, risk-aware reader: gates, thresholds and monitoring targets lead. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents an inconvenient regimen (continuous infusion, thrice-daily nebulisation, self-injection) without softening it. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at the general population; assumes willingness to engage with laboratory monitoring and route-specific protocols. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance (l.433-439) correctly weights the licensed local indication over the unresolved systemic one, which is the signal that matters for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging” or “antiaging”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Route of administration is stated formally throughout (“Injected locally”, “Intravenous regimen”, “Nebulised”, “Intracavernosal”); no “pill”, “shot” or “by mouth”. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | “Protocol” (l.446), “Time to effect” (l.487), “Benefits” (l.529), “Risk & Side Effects” (l.617), “Monitoring” (l.645), “Qualitative Assessment” (l.817), “Contraindications” (l.561), “Key Interactions” (l.582), tier labels and “Marker / Target / Why” (l.649-651) are byte-identical to the template. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template spans present; marker_#* is expanded to marker_1..12 and qualitative_item# to qualitative_item_1..6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Structural diff against [qrs_template] with text nodes stripped shows changes only inside data-qrs-var spans and the metadata block; CSS, website= spans, footer and disclaimer are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section used by the QRS is empty, so no empty-state phrasing is required. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER’s bold bullet labels verbatim: “Intravenous regimen for respiratory failure”, “Inhaled regimen”, “Intracavernosal regimen” (ER l.351-355). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | All 12 monitoring marker names reproduce the ER biomarker-table column verbatim (ER l.444-455). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters anywhere in the file; the ER’s tier and “Conflicted” emoji are stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Per-section condensation is applied as required: benefit and risk tiers are reduced to bare ER headings, gate items are stripped of consequence/mitigation clauses, marker_6_target is truncated, and qualitative items drop their trailing rationale. No section is carried over at ER length. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at l.2, immediately after <!doctype html> at l.1, before <head>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | ”—” at l.3 opens and “—” at l.13 closes; the preamble text on l.2 is outside the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment and duplicated nowhere on the sheet. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration is quoted, correctly, because “00:04” contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | l.4: er_filename: aviptadil_2026-0912-1219_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | l.5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | l.6: qrs_creation_date: 2026-0912-1536, correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | l.7: qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | l.8: qrs_creator_ai_fullname: Opus 5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number only; no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | l.9: qrs_filename: aviptadil_2026-0912-1219_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace or unnecessary quoting in any of the nine keys. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | l.22: “Aviptadil for Health & Longevity - Quick Reference Sheet”, matching canonical_topic with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | l.417: “Aviptadil for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | l.421: 09/12/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0912-1536. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | l.425: “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Subline is the unmodified template line; no badge, AKA line, version stamp or variant marker added. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | l.433-439 condenses ER Conclusion l.488-492: the two therapeutic worlds, the licensed local indication as strongest evidence, and the transient respiratory effect. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words, under the 60-word cap. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the three sentences traces to a distinct Conclusion passage (ER l.488, l.488-489, l.490). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; uses “synthetic copy of a natural signalling molecule”, “quietens immune cells”, “oxygen transfer” rather than VIP, VPAC, or PaO2/FiO2. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, odds ratios or confidence intervals; “briefly, but not survival” is qualitative. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items trace to the ER’s “Populations who should avoid Aviptadil” list under Key Interactions & Contraindications (ER l.316-325). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER populations are represented, in ER order (QRS l.564-577). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale removed, e.g. ER “…outside a supervised protocol, since exposure data are limited to isolated case reports” -> QRS l.577 “Pregnancy or breastfeeding outside a supervised protocol”. Leading “People with / Men with / People taking” stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Route and threshold qualifiers preserved: “(intracavernosal route)” l.564 and l.566, “(under 90 days)” l.568, “below 25%” and “(systemic route)” l.572-573. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify populations to avoid the intervention, so the empty-only condition is respected. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items trace to the ER interaction bullets at l.296-314. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine of the ER’s ten interaction bullets appear; anticoagulants is correctly omitted because it is already carried as a contraindication at QRS l.566. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Consequence and Mitigation clauses are stripped from every bullet; the em-dash gloss in the PDE5 parenthetical is removed (QRS l.586-587 vs ER l.298). |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved for every applicable item: (sildenafil, tadalafil), (alprostadil, papaverine), (glyceryl trinitrate, isosorbide mononitrate), (doxazosin, amlodipine, diuretics), (sacubitril/valsartan), (aspirin, ibuprofen, naproxen), (pseudoephedrine, phenylephrine), and the two supplement lists. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does identify interactions, so the empty-only condition is respected. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets derive from ER Therapeutic Protocol l.351-355. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three route-specific regimens (intravenous, inhaled, intracavernosal) are the ER’s only dosing-actionable bullets; the remaining Protocol bullets are contextual. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct actionable regimens, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content, e.g. l.453 “50 -> 100 -> 150 pmol/kg/hour” and l.457 “600, 1,200 then 1,800 pmol/kg per day” from ER l.351. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Erection, breathlessness and oxygenation are the only three time-to-effect aspects the ER states (l.412). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order matches benefit magnitude: Erection (High tier, ER l.140-146), Breathlessness (Medium, ER l.148-154), Oxygenation (Low, ER l.156-162). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content (QRS l.493-522). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the row is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers derive from ER Expected Benefits l.136-194. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit spans are present and populated (QRS l.531-548). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of the ER’s own benefit headings with magnitudes, citations and the Conflicted marker removed. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers have at least one ER item, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four tiers derive from ER Potential Risks & Side Effects l.214-274. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk spans are present and populated (QRS l.619-639). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of the ER’s own risk headings; frequencies and mechanistic text are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical frequencies or severity grades survive in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers have at least one ER item, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table derives from the ER Monitoring Protocol & Defining Success section (l.436-455). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 12 ER biomarker rows are reproduced, with targets and reasons verbatim (QRS l.655-801). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | l.806-811 carries the full ER cadence sentence from l.440, including the 4-week and 6-week/3-month review points. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | The list derives from the ER’s qualitative markers block at l.457-464. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present (QRS l.819-847), with trailing rationale trimmed on items 1 and 2. |
Issues 12/09/2026 15:44
Pass rate 100.00%. No issues found.